As demonstrated in Figure 1, the 5-year survival rates were 88.7% for women with hormone-receptor-positive disease, 87.5% for women with HER2-positive disease, and 70.0% for those with triple-negative breast cancer. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.